Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) - Cash Flow Conversion Efficiency

Latest as of December 2025: 0.074x

Based on the latest financial reports, Eckert & Ziegler Strahlen- und Medizintechnik AG (EUZ) has a cash flow conversion efficiency ratio of 0.074x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€18.75 Million ≈ $21.91 Million USD) by net assets (€253.42 Million ≈ $296.28 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Eckert & Ziegler Strahlen- und Medizinte to measure how much of total assets are equity-financed.

Eckert & Ziegler Strahlen- und Medizintechnik AG - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Eckert & Ziegler Strahlen- und Medizintechnik AG's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Eckert & Ziegler Strahlen- und Medizinte cash flow quality index to evaluate the quality of earnings relative to operating cash generation.

Eckert & Ziegler Strahlen- und Medizintechnik AG Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Eckert & Ziegler Strahlen- und Medizintechnik AG ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Troax Group AB
ST:TROAX
0.025x
Indocement Tunggal Prakarsa
JK:INTP
0.020x
Shanghai Baolong Automotive Corp
SHG:603197
0.037x
Tortoise Energy Infrastructure Closed Fund
NYSE:TYG
0.017x
Foshan Electrical and Lighting Co Ltd
SHE:000541
0.003x
Avino Silver & Gold Mines Ltd
TO:ASM
0.043x
Sinoseal Holding Co Ltd
SHE:300470
0.035x
Regional Container Lines Public Company Limited
BK:RCL
0.054x

Annual Cash Flow Conversion Efficiency for Eckert & Ziegler Strahlen- und Medizintechnik AG (2013–2025)

The table below shows the annual cash flow conversion efficiency of Eckert & Ziegler Strahlen- und Medizintechnik AG from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see Eckert & Ziegler Strahlen- und Medizinte (EUZ) total market value.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 €253.42 Million
≈ $296.28 Million
€58.41 Million
≈ $68.28 Million
0.230x -22.03%
2024-12-31 €225.21 Million
≈ $263.30 Million
€66.57 Million
≈ $77.83 Million
0.296x +39.76%
2023-12-31 €224.09 Million
≈ $261.99 Million
€47.40 Million
≈ $55.41 Million
0.212x +31.74%
2022-12-31 €213.63 Million
≈ $249.75 Million
€34.30 Million
≈ $40.10 Million
0.161x -8.70%
2021-12-31 €192.53 Million
≈ $225.08 Million
€33.85 Million
≈ $39.58 Million
0.176x -25.07%
2020-12-31 €148.92 Million
≈ $174.10 Million
€34.95 Million
≈ $40.86 Million
0.235x -19.06%
2019-12-31 €139.44 Million
≈ $163.02 Million
€40.43 Million
≈ $47.27 Million
0.290x +69.34%
2018-12-31 €123.88 Million
≈ $144.83 Million
€21.21 Million
≈ $24.80 Million
0.171x -25.00%
2017-12-31 €117.52 Million
≈ $137.39 Million
€26.83 Million
≈ $31.36 Million
0.228x +26.71%
2016-12-31 €110.08 Million
≈ $128.69 Million
€19.83 Million
≈ $23.19 Million
0.180x +16.19%
2015-12-31 €104.67 Million
≈ $122.37 Million
€16.23 Million
≈ $18.97 Million
0.155x +37.54%
2014-12-31 €94.49 Million
≈ $110.47 Million
€10.65 Million
≈ $12.45 Million
0.113x -30.65%
2013-12-31 €90.27 Million
≈ $105.53 Million
€14.68 Million
≈ $17.16 Million
0.163x --

About Eckert & Ziegler Strahlen- und Medizintechnik AG

F:EUZ Germany Medical Devices
Market Cap
$1.01 Billion
€865.40 Million EUR
Market Cap Rank
#9175 Global
#1172 in Germany
Share Price
€13.83
Change (1 day)
+1.24%
52-Week Range
€13.25 - €64.95
All Time High
€133.02
About

Eckert & Ziegler SE manufactures and sells isotope technology components worldwide. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of uveal melanomas; brain seed, HDR and brachytherapy; therapeutic and radiotherapy accessories… Read more